PharmaCaribe

PharmaCaribe is a clinical-stage biotechnology company dedicated to the development of innovative small molecule therapies for oncology and infectious diseases. The company's primary focus is its lead candidate, PC-02, a novel alkylating agent designed to treat refractory solid tumors by bypassing common drug resistance pathways. Clinical development efforts for PC-02 are currently centered on high-unmet-need areas such as pancreatic cancer, glioblastoma multiforme, and ovarian cancer. PharmaCaribe aims to improve patient outcomes through targeted cytotoxic mechanisms that offer enhanced efficacy and reduced toxicity compared to traditional chemotherapies. The company's research is supported by collaborations with leading academic institutions and clinical researchers in the field of oncology.